72 related articles for article (PubMed ID: 8095806)
1. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
Eur J Surg; 1993 Jan; 159(1):43-7. PubMed ID: 8095806
[TBL] [Abstract][Full Text] [Related]
2. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
3. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
4. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
[TBL] [Abstract][Full Text] [Related]
5. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
6. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
7. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
8. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
[TBL] [Abstract][Full Text] [Related]
10. Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorectal cancer surgery.
Tartter PI; Martinelli G; Steinberg B; Barron D
Cancer Detect Prev; 1986; 9(3-4):359-64. PubMed ID: 3488807
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
[TBL] [Abstract][Full Text] [Related]
13. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
[TBL] [Abstract][Full Text] [Related]
16. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
19. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
20. Reduction of postoperative immunosuppression with ranitidine in patients with cancer of the stomach or large bowel.
Altomare DF; Lupo L; Pannarale OC; Di Corcia MG; Memeo V
Eur J Surg; 1995 Feb; 161(2):109-13. PubMed ID: 7772628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
